Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reduning
- Development stage
- Phase 4
- Lead developer
- Lianyungang Kanion
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Reduning is a traditional Chinese medicine (TCM) botanical injection developed by Jiangsu Kanion Pharmaceutical. It is a standardized mixture of extracts from three medicinal herbs: *Artemisia annua* (sweet wormwood), *Gardenia jasminoides* (cape jasmine), and *Lonicera japonica* (Japanese honeysuckle). Reduning is widely used in China for its antipyretic, anti-inflammatory, and antiviral properties, particularly in the treatment of upper respiratory tract infections, acute bronchitis, and viral febrile illnesses. The formulation works by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, and it has demonstrated broad-spectrum antiviral activity against pathogens like influenza and enteroviruses. Beyond its established use in respiratory infections, Reduning has been investigated in clinical trials for the treatment of Chikungunya fever.
- Brand names
- Reduning
- Other names
- Reduning InjectionRe-Du-Ning
02
Targets
IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Reduning.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reduning.